Palisade Bio Company Top Insiders
PALI Stock | USD 2.40 0.04 1.64% |
Palisade Bio's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Palisade Bio suggests that almost all insiders are extremely bullish. Palisade Bio employs about 9 people. The company is managed by 7 executives with a total tenure of roughly 21 years, averaging almost 3.0 years of service per executive, having 1.29 employees per reported executive.
Palisade Bio's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-05-28 | Donald Allen Williams | Acquired 1000 @ 4.86 | View | ||
2024-05-24 | John David Finley | Acquired 1000 @ 4.81 | View | ||
2024-01-31 | Donald Allen Williams | Acquired 666 @ 9 | View |
Monitoring Palisade Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Palisade |
Palisade Bio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Palisade Bio's future performance. Based on our forecasts, it is anticipated that Palisade will maintain a workforce of under 9 employees by December 2024.Palisade Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.5853) % which means that it has lost $0.5853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1009) %, meaning that it created substantial loss on money invested by shareholders. Palisade Bio's management efficiency ratios could be used to measure how well Palisade Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.92. The current Return On Capital Employed is estimated to decrease to -1.2. As of now, Palisade Bio's Fixed Asset Turnover is decreasing as compared to previous years. The Palisade Bio's current Asset Turnover is estimated to increase to 0.04, while Total Assets are projected to decrease to under 12.3 M.The Palisade Bio's current Common Stock Shares Outstanding is estimated to increase to about 478.8 K, while Net Loss is projected to decrease to (13.7 M).
Palisade Bio Workforce Comparison
Palisade Bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 147. Palisade Bio holds roughly 9.0 in number of employees claiming about 6% of equities under Health Care industry.
Palisade Bio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Palisade Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Palisade Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Palisade Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 0.875 | 14 | 16 | 15,732 | 9,138 |
2024-03-01 | 1.3158 | 25 | 19 | 168,840 | 116,833 |
2023-12-01 | 3.8333 | 23 | 6 | 257,959 | 16,926 |
2023-09-01 | 0.6667 | 6 | 9 | 60,342 | 143,563 |
2023-06-01 | 3.1667 | 19 | 6 | 339,359 | 7,194 |
2023-03-01 | 1.0 | 4 | 4 | 136,636 | 52,500 |
2022-09-01 | 2.0 | 4 | 2 | 166,831 | 480.00 |
2022-03-01 | 6.0 | 6 | 1 | 286,300 | 1,800 |
2021-09-01 | 4.5 | 9 | 2 | 32,999 | 377,474 |
2019-09-01 | 1.3333 | 8 | 6 | 947,025 | 231,175 |
2017-09-01 | 4.0 | 4 | 1 | 60,129 | 0.00 |
2016-03-01 | 0.6667 | 2 | 3 | 99,578 | 2,776,267 |
2015-12-01 | 0.2143 | 3 | 14 | 296,369 | 615,276 |
2015-09-01 | 1.0 | 9 | 9 | 2,627,456 | 3,167,906 |
2015-06-01 | 0.3333 | 2 | 6 | 120,000 | 273,682 |
2015-03-01 | 2.0 | 2 | 1 | 486,134 | 5,000 |
2014-09-01 | 1.0 | 5 | 5 | 349,911 | 155,000 |
2014-06-01 | 0.4545 | 5 | 11 | 72,735 | 118,534 |
2014-03-01 | 0.625 | 5 | 8 | 1,593,482 | 697,779 |
2013-09-01 | 0.125 | 1 | 8 | 50,000 | 278,800 |
2013-06-01 | 1.0 | 5 | 5 | 219,880 | 49,400 |
2013-03-01 | 0.75 | 3 | 4 | 1,292,579 | 50,400 |
2012-09-01 | 0.5 | 1 | 2 | 5,000,000 | 123,821 |
2012-06-01 | 2.3333 | 7 | 3 | 1,927,588 | 284,790 |
2011-03-01 | 0.4 | 2 | 5 | 38,367 | 39,802 |
2010-12-01 | 2.6667 | 8 | 3 | 947,988 | 60,000 |
2009-09-01 | 1.0 | 4 | 4 | 70,000 | 910,000 |
2008-03-01 | 0.3889 | 7 | 18 | 4,209,700 | 47,700 |
2007-09-01 | 0.3333 | 2 | 6 | 340,833 | 20,000 |
2007-06-01 | 0.6 | 3 | 5 | 3,010,000 | 180,000 |
Palisade Bio Notable Stakeholders
A Palisade Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Palisade Bio often face trade-offs trying to please all of them. Palisade Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Palisade Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
J Finley | CEO Director | Profile | |
Joerg Heyer | Head Medicine | Profile | |
Ryker Willie | Senior Controller | Profile | |
Sharon McBrayer | Director Operations | Profile | |
Mitchell MD | Chief Officer | Profile | |
Robert McRae | VP Devel | Profile | |
MD FAAAAI | Chief Officer | Profile |
About Palisade Bio Management Performance
The success or failure of an entity such as Palisade Bio often depends on how effective the management is. Palisade Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Palisade management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Palisade management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.88) | (0.92) | |
Return On Capital Employed | (1.14) | (1.20) | |
Return On Assets | (0.88) | (0.92) | |
Return On Equity | (1.09) | (1.14) |
Palisade Bio Workforce Analysis
Traditionally, organizations such as Palisade Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Palisade Bio within its industry.Palisade Bio Manpower Efficiency
Return on Palisade Bio Manpower
Revenue Per Employee | 27.8K | |
Revenue Per Executive | 35.7K | |
Net Loss Per Employee | 1.4M | |
Net Loss Per Executive | 1.8M | |
Working Capital Per Employee | 1.2M | |
Working Capital Per Executive | 1.5M |
Complementary Tools for Palisade Stock analysis
When running Palisade Bio's price analysis, check to measure Palisade Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Palisade Bio is operating at the current time. Most of Palisade Bio's value examination focuses on studying past and present price action to predict the probability of Palisade Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Palisade Bio's price. Additionally, you may evaluate how the addition of Palisade Bio to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |